Breaking News

Rentschler Biopharma, VarmX Partner on Coagulation Therapy

Rentschler to manufacture VarmX’s VMX-C001 for Phase 3 development and potential commercialization.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Rentschler Biopharma

Rentschler Biopharma, a global CDMO for biopharmaceuticals, and VarmX, a biotech company developing direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and treatment of inherited coagulation disorders, entered a collaboration for the manufacture VarmX’s lead program, VMX-C001, for Phase 3 development and potential commercialization. VMX-C001 is a novel treatment to restore blood coagulation in patients requiring urgent surgery or experiencing severe bleeding while on FXa DOAC...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters